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Introduction
The introduction of blood-based tests for M. tuberculosis 
(Mtb) infection approximately 15 years ago was a turning 
point for diagnosis of latent tuberculosis (TB). Interferon-
gamma release assays (IGRAs), which measure Mtb antigen-
specific T cell responses, include the ELISpot-based 
T-SPOT.TB (Oxford Immunotec, Abingdon, UK) and the 
ELISA-based QuantiFERON Gold In-Tube (QFT-GIT; 
Qiagen, Hilden, Germany). These assays overcame many 
of the limitations of the >100-year-old tuberculin skin test 
(TST) for diagnosing Mtb infection. The greatest advantage 
of IGRA over TST is that they are not confounded by prior 
vaccination with Bacille Calmette-Guerin (BCG) (1-3). 
This is because TST measures a localised hypersensitivity 
reaction to purified protein derivative (PPD), a crude 
preparation of proteins from heat-killed Mtb cultures which 
includes antigens present in BCG, whereas IGRAs measure 
T cell responses to antigens coded from a specific segment 
of the Mtb genome which is absent from BCG, region of 
difference 1 (RD1). The impact of this is a greatly improved 
diagnostic specificity for Mtb infection in IGRAs compared 
to TST, and thus far fewer false-positive diagnoses of latent 
TB infection (LTBI) (1-3).
Whilst IGRAs had major positive implications for the 
diagnosis of LTBI, they do have limitations. Sensitivity, 
whilst higher than TST, is typically limited, particularly in 
key subgroups such as children and immunocompromised 
patients (4-7). Furthermore, their prognostic power to 
predict progression from LTBI to active TB disease and 
their role in diagnosis of active TB have, until recently, 
been unclear (4). A number of landmark studies conducted 
over the past five years have addressed some of these 
uncertainties surrounding existing IGRAs and aimed to 
develop new and improved IGRAs with increased sensitivity, 
including among patient subgroups in whom diagnosis of 
both active and latent TB is notoriously challenging (8-12). 
Alongside the evolving landscape of TB diagnostics, 
efforts to develop improved TB vaccines to prevent spread 
of infection are ongoing due to the limited effectiveness of 
BCG. ESAT-6 is an important candidate antigen for novel 
vaccines, and two vaccines in the pipeline, Hybrid 1-IC31 
(13,14) and H56:IC31 (15,16), contain ESAT-6; phase II 
trials of H56:IC31 are currently ongoing. Licensure and 
deployment of these vaccines would, however, present a 
challenge: immunisation with ESAT-6-containing vaccines 
will likely result in false-positive IGRA results in individuals 
without Mtb infection, just as BCG vaccination causes 
false-positive TST results (15). This would limit the use of 
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IGRAs, the current standard-of-care for diagnosing Mtb 
infection. Whilst licensure of the these vaccines is at least 
a few years in the future, ongoing clinical trials, which use 
prevention of infection as an endpoint (17), already demand 
a practical solution to this immunological conundrum. 
A novel ESAT-6 free IGRA
In their recent article published in the Journal of Clinical 
Infectious Diseases, Nemes et al. reported a proof-of-concept 
assessment of a novel ESAT-6-free IGRA utilising the QFT-
based methodology (18). The assay was previously designed 
following an initial screening of candidate Mtb antigens 
and peptides (selected based on immune recognition and 
specificity properties) among cohorts of uninfected and 
Mtb-infected individuals and TB patients from Greenland 
and Egypt, allowing creation of an ESAT-6-free antigen 
cocktail of four selected antigens [CFP-10, EspC (Rv3615c), 
EspF and Rv2348] (19). In the original study (19), the 
authors defined a cut-off for the assay among TB patients 
from Egypt and healthy controls from Denmark, and 
performed a cross-validation of the assay against the existing 
QFT assay in TB patients and healthy adults from a high 
TB burden setting, Tanzania, in which the ESAT-6-free 
IGRA performed at least as well as the existing test.  
The first aim of Nemes et al.’s study was to confirm 
recognition of the antigen cocktail incorporated in 
the ESAT-6-free IGRA in a high TB burden setting, 
South Africa (18). This is a logical goal given that the 
antigens were originally selected using cohorts from low 
[Denmark; incidence risk 5.1 per 100,000 population (20)] 
and intermediate [Egypt; incidence risk 13.0 per 100,000 
population (20)] TB burden settings. As Ruhwald et al. 
previously validated the novel assay among cohorts from 
Tanzania (19), Nemes et al.’s study builds on this by 
confirming antigen recognition within a second high TB 
burden setting. Further, Nemes et al. specifically sought 
to conduct the evaluations in South African adolescents 
on the basis that they are a target group for trials of new 
interventions to prevent TB, including new vaccines (18). 
Ex vivo T cell responses were measured following 
whole blood stimulation with each antigen individually 
and combined in a cohort of 60 South African adolescents, 
35 of whom tested QFT-positive in parallel. The authors 
demonstrated a clear and strong correlation between QFT 
and ESAT-6-free IGRA responses, and it thus follows 
that IFN-γ levels measured in ESAT-6-free IGRA were 
significantly higher in QFT-positive compared to QFT-
negative adolescents (18). The authors acknowledge that 
the ESAT-6-free IGRA response was largely driven by 
CFP-10 and Rv3615c, and this is evident in their Box and 
Whisker plot of IFN-γ response magnitudes for each of 
the individual antigens. IFN-γ responses to both EspF and 
Rv2348 were mostly small and not significantly different 
in QFT-positive and negative adolescents. This begs the 
question of the incremental value, if any, of including these 
additional antigens in this population. This uncertainty also 
exists for Ruhwald et al.’s earlier study in Tanzanian cohorts, 
for whom IFN-γ response data were not provided by 
individual antigen (19). Inclusion of each additional antigen 
will very likely incrementally reduce the specificity of an 
assay, and have attendant cost implications. It is therefore 
important to evaluate and publish how the ESAT-6-free 
IGRA performs in the absence of EspF and/or Rv2348. 
The second stated aim was to define a ‘diagnostic 
algorithm’ for the ESAT-6-free IGRA, by which the authors 
meant defining a cut-off for scoring the assay as positive (18). 
The authors measured ESAT-6-free IGRA IFN-γ 
responses among a cohort of South African adults with 
microbiologically confirmed pulmonary TB and a separate 
cohort of healthy adults from Denmark with no history of 
Mtb exposure. Receiver operator curve (ROC) analysis was 
then used to define a cut-off of 0.61 IU/L for ESAT-6-free 
IGRA for differentiating patients with active TB (and thus 
Mtb infection) versus Mtb uninfected individuals with 82% 
sensitivity and 96% specificity. 
ROC analysis in this scenario requires comparison of 
confirmed Mtb infected versus uninfected persons, which 
can be a challenge given the lack of a gold-standard test 
for LTBI. Nemes et al.’s analysis used largely appropriate 
cohorts and methodology for defining assay cut-offs. Active 
TB was used as a proxy for Mtb infection on the basis 
that Mtb infection is a pre-requisite for disease; while the 
‘control’ group of Danish adults are at very ‘low risk’ of Mtb 
infection, they cannot be confirmed as Mtb-uninfected as 
there is currently no rule-out test for LTBI. 
With the apparent strategy of the study being to 
evaluate a novel ESAT-6-free IGRA to effectively replace 
QFT for individuals immunised with ESAT-6-containing 
vaccines, the sensitivity and specificity achieved with the 
selected cut-off were roughly equivalent to QFT, albeit 
with wide confidence intervals (18). The cut-off for ESAT-
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6-free IGRA was selected by the authors as the IFN-γ 
concentration that yielded a specificity no more than five 
per cent lower than QFT. Notably, however, QFT (with 
the manufacturer recommended cut-off of 0.35 IU/mL) 
had 92% sensitivity and 100% specificity for active TB; 
estimates that are somewhat higher than what the majority 
of available literature suggests (6,7,9). Whether or not the 
unusually high sensitivity and specificity of QFT were due 
to selection bias in these cohorts, they suggest that the 
cohorts are unrepresentative of other populations, limiting 
the generalisability of results. 
Notably, Ruhwald had previously defined a cut-off 
for the novel ESAT-6-free IGRA among patients with 
confirmed TB from Egypt and Mtb-unexposed controls 
from Denmark (19). In that study, a cut-off of between 0.15 
and 0.30 IU/mL gave a sensitivity of 89% and specificity 
of 99–100%. Sensitivity and specificity of QFT (84% 
and 97%, respectively) were again higher than the wider 
literature indicates (6,7), but similar to ESAT-6-free IGRA. 
Among Ruhwald et al.’s validation cohort of Tanzanian TB 
patients, sensitivity of the ESAT-6-free IGRA for active TB 
was 84%, whilst sensitivity of QFT was 79% (19). It is not 
clear why Nemes et al. aimed to define a new cut-off for the 
novel assay using the South African cohort and not evaluate 
the assay using the previously defined cut-off that showed 
promising diagnostic accuracy in the Tanzanian cohorts (18). 
So far, neither study has defined where the test would 
fit into a diagnostic algorithm for clinical evaluation of 
suspected LTBI.
Nemes et al. thirdly aimed to evaluate the diagnostic 
performance of ESAT-6-free IGRA compared to QFT (18). 
This component of the study was conducted using a cohort 
of 200 healthy South African adolescents screened for a trial 
for prevention of Mtb infection. Participants were tested 
for Mtb infection using both QFT and ESAT-6-free IGRA, 
and ESAT-6-free IGRA responses were compared in QFT-
positive and QFT-negative individuals.
Here, rather than comparing the diagnostic performance 
of ESAT-6-free IGRA with QFT, the authors have 
benchmarked ESAT-6-free IGRA against QFT as a 
reference standard. Again, given their goal of replacing 
QFT with ESAT-6-free IGRA using QFT as a ‘gold 
standard’, measuring concordance of the two assays is a 
valid approach. The correlation between the two assays, as 
found in the South African cohort used to confirm antigen 
recognition, was high. 
The above series of analyses presented by Nemes et al. 
thus collectively indicate that ESAT-6-free IGRA has high 
concordance with QFT and, if the findings are confirmed in 
independent populations, support the notion that ESAT-6-
free IGRA could replace QFT in clinical trials of ESAT-6-
containing vaccines. 
However, given the limitations of currently available 
IGRAs, there is the opportunity and a clinical need to go 
beyond a product that is merely equivalent to QFT. Does 
ESAT-6-free IGRA in fact perform better than QFT? 
In Nemes et al.’s study, 11 QFT-negative patients tested 
positive in ESAT-6-free IGRA (18). The assumption 
inherent in the authors’ adoption of QFT as reference 
standard is that these patients are truly Mtb-uninfected 
(because they are QFT-negative) and falsely positive in 
ESAT-6-free IGRA. However, given our knowledge of 
the diagnostic performance of QFT (6,7), it is perhaps 
likely that at least a proportion of these patients were in 
fact Mtb infected, and thus falsely negative in QFT and 
truly positive in ESAT-6-free IGRA. Similarly, of the 
seven patients testing positive by QFT and negative by 
ESAT-6-free IGRA, how many were Mtb-infected (QFT 
true-positive and ESAT-6-free IGRA false-negative), 
and how many were Mtb-uninfected (QFT false-positive 
and ESAT-6-free-IGRA true-negative)? These questions 
can only be resolved if the study design incorporates 
a reference standard (e.g., microbiological, clinical or 
epidemiologic) that is independent of the two assays being 
evaluated (21,22). 
In the final aim of their study, Nemes et al. sought to 
assess the variability of ESAT-6-free IGRA blood collection 
tubes (18). This was carried out using a cohort of 12 healthy 
South African adults with no evidence of active TB or 
HIV infection. Whilst a fairly preliminary assessment due 
to limited evaluations performed, IFN-γ responses across 
ESAT-6-free IGRA tube lots correlated strongly. For most 
validatory evaluations, interpretation of results is limited 
by their wide confidence intervals resulting from the small 
numbers of participants. Nonetheless, a degree of tube-
associated variability detected in the study prompted 
the authors to highlight the need for improvement of 
the blood collection tubes. It should additionally be 
considered that the authors used stricter procedures than 
those recommended by QFT manufacturers, so in a real-
life routine setting assay performance may be poorer than 
reported in the study by Nemes et al. 
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The future of ESAT-6-free IGRA and IGRA
The omission of ESAT-6 from IGRA without loss of 
diagnostic sensitivity was made possible by inclusion of the 
remarkably immunogenic antigen Rv3615c (23). Although 
Rv3615c is encoded outside the RD1 genomic segment and 
the gene is therefore present in BCG, the antigen is not 
secreted by BCG and BCG-vaccination does not induce 
a detectable T cell response to it. Hence, as well being 
an exceptionally strong target of T cells in Mtb-infected 
persons, it is also functionally highly Mtb-specific (23). 
This discovery opened the door to development of ESAT-
6-free IGRA and second-generation IGRA with improved 
diagnostic sensitivity without compromising diagnostic 
specificity (9), as originally predicted when Rv3615c was 
first characterised (23). 
We recently reported a large prospective cohort study 
conducted in routine clinical practice in the UK which 
evaluated the role of existing and second-generation IGRAs 
(containing Rv3615c) in the diagnostic work up of active 
TB (9). We described a novel second-generation IGRA 
using the ELISpot platform and incorporating ESAT-6, 
CFP-10 and Rv3615c with 94% sensitivity for culture-
confirmed TB. Specificity, when comparing patients with 
active TB to TST-negative controls with no history of 
Mtb exposure, was 91.3%. Diagnostic performance of the 
second-generation IGRA was significantly better than both 
QFT and T-SPOT.TB and conferred a sufficiently high 
negative predictive value to support a rapid rule-out of 
suspected TB in settings with a low or moderate pre-test 
probability of TB. Furthermore, we also tested an ELISpot-
based ESAT-6-free IGRA incorporating CFP-10, Rv3615c 
and Rv3879c, which demonstrated equivalent sensitivity and 
specificity (93.4% and 90.3%, respectively) to the second-
generation IGRA that included ESAT-6.
Notably, the ELISpot-based assay used the full length 
of the antigen, whilst Nemes et al.’s QFT-based assay 
used just the carboxy terminal half (aa54-103) (18). Prior 
epitope mapping of Rv3615c suggested that, whilst the 
most strongly recognised epitopes are situated within 
the carboxy terminal, excluding peptides in the first half of 
the protein sequence could reduce the proportion of Mtb-
infected individuals detected using the assay (23). Indeed, 
when peptides spanning the full antigen are used, very high 
sensitivity is conferred (23), providing a clear rationale for our 
design of the second-generation ELISpot-based IGRA (9). 
In an independent Chinese study comparing the diagnostic 
performance of T-SPOT.TB with and without addition of 
Rv3615c in patients with suspected TB, sensitivity of the 
Rv3615c-containing assay for culture-confirmed active TB was 
92.2%, similar to the UK study (12). Specificity was lower, 
as would be expected when evaluating IGRA for diagnosis 
of active TB in a high-incidence setting owing to a high 
prevalence of LTBI in patients with illnesses other than TB. 
Conclusions
With existing ESAT-6-containing vaccines rapidly 
progressing through pre-licensure trial phases (13-16), 
and the antigen increasingly being recognised as a strong 
candidate for incorporation into novel vaccines, there is 
a clear need for an accompanying test for Mtb infection 
that is not confounded by prior immunisation with an 
ESAT-6-containing vaccine (9,19). Nemes et al. have 
demonstrated that a QFT-based ESAT-6-free IGRA 
incorporating Rv3615c performs equivalently to the 
existing QFT, providing a suitable substitute for QFT in 
ongoing vaccine trials (18). Incorporation of Rv3615c into 
the ELISpot (T-SPOT.TB) platform provides a second-
generation IGRA with higher diagnostic sensitivity 
than any preceding IGRA (Figure 1), delivering the first 
meaningful advance on IGRA since their introduction 15 
years ago (24). This new assay, unlike other IGRAs, has 
clinical utility in the diagnostic evaluation of active TB 
by facilitating rapid rule-out of suspected TB from the 
differential diagnosis (9). 
In summary, the process of development and deployment 
of IGRA, the first T cell-based diagnostic test, has led 
to a recognition of their limitations in clinical practice 
and renewed translational research to further develop 
the technology to overcome those limitations (1-3,9). 
Meanwhile, translational research to develop improved TB 
vaccines has identified another limitation of IGRA if ESAT-
6-based vaccines are rolled out and this, in turn, is now 
influencing development of ESAT-6-free IGRAs. Applying 
our knowledge of the cell-mediated immune response to 
Mtb to improve clinical care through better diagnostics and 
to improve public health through more effective vaccines 
thus provides a compelling, and still unfolding, story of 
intersecting strands of translational research.
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